Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) gapped down before the market opened on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $8.04, but opened at $7.77. Aura Biosciences shares last traded at $7.45, with a volume of 112,681 shares trading hands.

The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10).

Trending Headlines about Aura Biosciences

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and an $18 price target. Although the target was reduced from $24, it remains substantially above the stock’s recent $7.39 level, signaling that the analyst sees significant potential upside. HC Wainwright projects 2027 quarterly losses of $0.40 to $0.42 per share. StreetInsider analyst report
• Neutral Sentiment: The company is refocusing research and development on eye cancer. The strategic shift could concentrate resources on Aura’s core pipeline, but near-term execution and funding risks remain as the company continues to operate at a loss. Fierce Biotech workforce and management changes article
• Neutral Sentiment: Reported short-interest data provides no useful trading signal. The reported short interest was zero, with a zero days-to-cover ratio; the data also showed an invalid percentage change, suggesting the figures may be incomplete or unreliable.
• Negative Sentiment: Aura reported a second-quarter 2026 loss of $0.48 per share, missing the consensus estimate of a $0.38 loss. The $0.10-per-share shortfall reinforces concerns about operating expenses and the company’s path toward profitability. Analysts expect a full-year loss of approximately $1.73 per share. Aura Biosciences second-quarter 2026 results
• Negative Sentiment: Aura is reportedly eliminating about 20% of its workforce and changing its executive structure. While the cuts may reduce costs, investors may interpret them as evidence of financial pressure or delays in the development strategy.

Analysts Set New Price Targets

AURA has been the topic of several analyst reports. Wall Street Zen upgraded Aura Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. Leerink Partners set a $17.00 price target on Aura Biosciences in a report on Tuesday, May 12th. Finally, HC Wainwright lowered their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.50.

Insiders Place Their Bets

In other Aura Biosciences news, insider Anthony S. Gibney sold 12,824 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the transaction, the insider owned 265,354 shares in the company, valued at approximately $1,703,572.68. The trade was a 4.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of Aura Biosciences

A number of institutional investors have recently modified their holdings of the business. Parallel Advisors LLC raised its position in Aura Biosciences by 130.4% in the first quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock worth $38,000 after acquiring an additional 3,206 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after purchasing an additional 2,104 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $59,000. Water Island Capital LLC acquired a new position in shares of Aura Biosciences during the 3rd quarter worth $64,000. Finally, Invesco Ltd. purchased a new position in shares of Aura Biosciences in the 2nd quarter valued at about $76,000. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Aura Biosciences Price Performance

The company’s 50 day moving average is $6.96 and its 200 day moving average is $6.71. The stock has a market cap of $751.28 million, a price-to-earnings ratio of -4.18 and a beta of 0.40.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.